Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Millions |
3 Months Ended |
|
|
|
|
Sep. 30, 2017 |
Jun. 30, 2017 |
Aug. 01, 2016 |
Mar. 14, 2016 |
Nov. 03, 2014 |
| Advanced Cell Diagnostics (ACD) [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
$ 75.0
|
$ 50.0
|
|
|
|
| Business Combination, Liabilities Arising from Contingencies, Amount Recognized |
|
|
$ 37.0
|
|
|
| Zephyrus [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
7.0
|
3.5
|
|
|
|
| Business Combination, Liabilities Arising from Contingencies, Amount Recognized |
|
|
|
$ 6.5
|
|
| CyVek, Inc. [Member] |
|
|
|
|
|
| Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
35.0
|
$ 35.0
|
|
|
|
| Business Combination, Liabilities Arising from Contingencies, Amount Recognized |
|
|
|
|
$ 35.0
|
| Payment for Contingent Consideration Liability |
35.0
|
|
|
|
|
| Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member] |
|
|
|
|
|
| Business Combination, Liabilities Arising from Contingencies, Amount Recognized |
$ 78.5
|
|
|
|
|